Several RTKs, such as Human Epidermal Growth Factor Receptor 2 (HER2), Mesenchymal–Epithelial Transition Factor (MET), and Fibroblast Growth Factor Receptor 2 (FGFR2), have already emerged as potential therapeutic targets in GC, underscoring the clinical relevance of this receptor class [10]. Here, MET is linked to gastric cancer.